EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry launched in late October 2015 as a companion title within the EJNMMI journal family, aimed at chemists, pharmacists, biologists and basic scientists working on new imaging and radionuclide-based therapeutic agents. Its scope covers novel radionuclide production methods, radiochemistry and radiolabelling, new radiopharmaceuticals with first biological evaluation, and molecular imaging agents more broadly (including optical and MRI probes and hybrid probes), as well as best-practice and harmonisation guidance and legislative/regulatory position papers relevant to translating agents to the clinic.

It received its first Clarivate impact factor in 2023, covering the 2022 JCR release, at 4.6, and is indexed in the Emerging Sources Citation Index under chemistry, medicinal; radiology, nuclear medicine & medical imaging; and chemistry, inorganic & nuclear categories.

As a Springer Nature/SpringerOpen title, it is fully open access, distinguishing it from its parent journal EJNMMI, which is hybrid.